 WARMER, Pa., Jan. 04, 2022 GLOBE NEWSWIRE -- Arbutus Biopharma Corporation Nasdaq: ABUS, a clinical-stage biopharmaceutical company primarily focused on discovering, developing and commercializing a broad portfolio of assets with different modes of action to provide a cure for people with chronic hepatitis B virus infection and to treat coronaviruses including COVID-19, today announced that the Company will participate in a virtual fireside chat at the H.C. Wainwright Bioconnect Virtual Conference taking place January 10 - 13, 2022. 